Skip to content
Research/Immune Modulation/Recaticimab

Recaticimab

Recaticimab is a novel monoclonal antibody that targets specific immune pathways to modulate immune responses. Its primary mechanism involves altering immune cell activity, which may have implications for treating autoimmune conditions and enhancing immune resilience. This compound is relevant for longevity and health optimization as it could potentially reduce chronic inflammation and improve immune system function.

Intelligence Profile

Science

Recaticimab is a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein involved in cholesterol regulation. According to the study titled "Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering" (PMID: 42274993), Recaticimab has been engineered to bind with high affinity to PCSK9, preventing it from interacting with low-density lipoprotein receptors (LDLR) on liver cells. This interaction is crucial because PCSK9 normally promotes the degradation of LDLR, which are responsible for clearing LDL cholesterol from the bloodstream.

By inhibiting PCSK9, Recaticimab increases the number of LDL receptors available on the surface of liver cells, thereby enhancing the clearance of LDL cholesterol and leading to lower blood cholesterol levels. Furthermore, the Fc-engineering of Recaticimab is designed to prolong its half-life and enhance its duration of action, ensuring a more sustained lipid-lowering effect compared to other monoclonal antibodies targeting PCSK9.

The Phase 1b/2 study detailed in "Impact of PCSK9 Inhibitor Recaticimab on Hyperlipidemia and Plasma Glucose" (PMID: 41196105) supports these findings by showing a significant reduction in LDL cholesterol in patients with hyperlipidemia. The systematic reviews and meta-analyses (e.g., PMID: 41801769 and 41585950) further confirm Recaticimab's efficacy in reducing cholesterol levels in patients with dyslipidemia and hypercholesterolemia.

Disclaimer: This information is for educational purposes and not a substitute for professional medical advice. Always consult a healthcare provider for medical issues.